Answers are grounded in this paper and cite their sources.
This study aims to investigate the effects of MaquiBright ® , also known as BrightSight ® , a standardized maqui berry extract, on improving eye dryness and fatigue in Japanese subjects (aged 30–60 years) experiencing eye dryness, eye fatigue, and ≥4 h of visual display terminal (VDT) work daily. Seventy-four participants were equally but randomly assigned to either a MaquiBright ® (MB) or a placebo (P) group, wherein each participant consumed one capsule daily for 4 weeks of the appropriate treatment (MaquiBright ® 60 or 0 mg). Eye dryness and fatigue were measured using the Schirmer's test, tear break-up time (BUT) test, pupillary response, and flicker test before intake and 4 weeks after intake. Furthermore, subjective symptoms were assessed using the Visual Analogue Scale (VAS) method and the Dry Eye–related Quality of Life Score (DEQS) questionnaire. The MB group demonstrated a significantly higher lacrimal fluid production in both eyes (increased 6.4 ± 8.1 mm, P = 0.005) in Schirmer's test compared to the P group before VDT load (playing a video game) at 4 weeks after intake. In the VAS method after VDT load, the reduction of subjective symptoms in eye fatigue ( P = 0.047) and stiff shoulders ( P = 0.035) were significantly higher in the MB group than in the P group as well as bothersome ocular symptoms ( P = 0.037) by the DEQS. No adverse events were reported. Thus, the consumption of 60 mg of MaquiBright ® per day for 4 weeks reduced eye dryness and seemed to alleviate eye fatigue.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: